Genmab A/S at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 12, 2022 / 02:00PM GMT
James Daniel Gordon - JPMorgan Chase & Co, Research Division - Senior Analyst

Good morning, and good afternoon. I'm James Gordon, JPMorgan European Pharma and Biotech analyst. And today, at the JPMorgan Conference, I have the pleasure of introducing the Genmab presentation and Q&A. So Genmab President and CEO, Jan van de Winkel, joining us for a 20-minute presentation, and then we're going to do 20 minutes of Q&A.

And so with that said, thanks a lot for joining us today, Jan, and over to you for the presentation.

Jan G.J. van de Winkel - Genmab A/S-Co-Founder - President & CEO

Thanks, James, for the introduction. It's a pleasure to be with you all again at the Annual JPMorgan Healthcare Conference as we kick off 2022. Slides from today's presentation will be available for download on our website immediately after the event. So let's get started.

Next slide, please. I'm now on Slide #2. This presentation may contain forward-looking statements and as such may contain

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot